Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sangamo Therapeutics, Inc.”

106 pharma patents match "Sangamo Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 106
Index total 30,257
Page 4 / 5

Quick answer

This filtered view shows 106 pharmaceutical patents matching "Sangamo Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

106 results for “Sangamo Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 10435441

    HTT repressors and uses thereof

    Sangamo Therapeutics, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  2. US 10407476

    Methods and compositions for treating hemophilia

    Sangamo Therapeutics, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  3. US 10370680

    Method of treating factor IX deficiency using nuclease-mediated targeted integration

    Sangamo Therapeutics, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  4. US 10369201

    Methods and compositions for treating Huntington's disease

    Sangamo Therapeutics, Inc. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  5. US 10344271

    Modified zinc finger binding proteins

    Sangamo Therapeutics, Inc. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  6. US 10293000

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted
  7. US 10265377

    Methods and compositions for treating Huntington's Disease

    Sangamo Therapeutics, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  8. US 10253333

    DNA-binding proteins and uses thereof

    Sangamo Therapeutics, Inc. · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted
  9. US 10227610

    Methods and compositions for enhancing nuclease-mediated gene disruption

    Sangamo Therapeutics, Inc. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted
  10. US 10155011

    Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

    Sangamo Therapeutics, Inc. · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted
  11. US 10143760

    Liver-specific constructs, factor VIII expression cassettes and methods of use thereof

    Sangamo Therapeutics, Inc. · Granted Dec 4, 2018 · Expires Nov 29, 2038

    granted
  12. US 10117899

    Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells

    Sangamo Therapeutics, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted
  13. US 10113207

    Methods and compositions for targeted single-stranded cleavage and targeted integration

    Sangamo Therapeutics, Inc. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted
  14. US 10081661

    Methods and compositions for genome engineering

    Sangamo Therapeutics, Inc. · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted
  15. US 10072066

    Methods and compositions for treatment of a beta thalessemia

    Sangamo Therapeutics, Inc. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  16. US 10046028

    Methods and compositions for modulating PD1

    Sangamo Therapeutics, Inc. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted
  17. US 9982245

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  18. US 9963715

    Methods and compositions for treatment of a genetic condition

    Sangamo Therapeutics, Inc. · Granted May 8, 2018 · Expires May 3, 2038

    granted
  19. US 9956247

    Method of treating lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  20. US 9957501

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  21. US 9957526

    Delivery methods and compositions for nuclease-mediated genome engineering

    Sangamo Therapeutics, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  22. US 9943565

    Methods and compositions for treating trinucleotide repeat disorders

    Sangamo Therapeutics, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  23. US 9937207

    Targeted disruption of T cell receptor genes using talens

    Sangamo Therapeutics, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  24. US 9914940

    Targeted integration into the PPP1R12C locus

    Sangamo Therapeutics, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted